Curriculum vitae

Dr. med. Livius Penter
46 Harvard Avenue, Apt 5
Brookline, MA
02446
USA

+1 (857) 234 0639
+49 (157) 5846 7238
Livius_Penter@dfci.harvard.edu
Livius.Penter@charite.de
@livius_tacitus

Born October 02, 1987 in Dresden, Germany
0000-0002-9060-0207
www.penterlab.org

Research

	Dana-Farber Cancer Institute, USA
Since 10/2019	Postdoctoral research fellow (Wu Lab) *CTLA-4 blockade for relapsed myeloid malignancies after transplantation*
	Charité – Universitätsmedizin Berlin, Germany
06/2015 – 09/2019	Postdoctoral research fellow (Hansmann Lab) *Immunologic biomarkers and therapeutic targets in rectal cancer*
	Laboratory of Pediatric Molecular Biology Berlin, Germany
08/2009 – 05/2015	Medical thesis (Prof. Hagemeier) *Development of a lentiviral shRNA screen in SH-EP neuroblastoma cells*
	Research Institute of Molecular Pathology Vienna, Austria
06 – 08/2013	Vienna Biocenter Summer School (Zuber Lab)
	Max Planck Institute of Molecular Cell Biology Dresden, Germany
09/2005 – 06/2007	School project: *Phylogenetic analysis of proteins using bioinformatics tools*

Education

	Berlin Institute of Health
07/2016 to 07/2018	Junior Clinician Scientist
	Charité – Universitätsmedizin Berlin
01/2015 – 09/2019	Internal Medicine and Hematology/Oncology
05/2015	Medical thesis with grade 1.0 (magna cum laude)
11/2014	Medical state examination with grade 1.33 (1.0=best, 5.0=bottom)
	Martin-Andersen-Nexö-Gymnasium Dresden, Germany
06/2007	High school diploma with grade 1.0 (1.0=best, 6.0=bottom) *Prizes in informatics competitions and work as administrator of computer pool*

International experience

	McGill University Montreal, Canada
02 – 04/2014	Clinical electives in cardiology and nephrology
	Université Diderot Paris VII, France
09/2013 – 02/2014	Clinical electives in general surgery and medical oncology
	Université Pierre et Marie Curie Paris VI, France
08/2011 – 06/2012	ERASMUS exchange
	Bangalore Baptist Hospital, India
02 – 03/2010	Clinical elective in general surgery
	Morrin High School, Alberta, Canada
09/2004 – 06/2005	High school diploma

Scholarships and awards

01-06/2023	EHA-EMBL/EBI Computational Biology Training in Hematology (CBTH)
07/2022	ASH Scholar Award
12/2020 and 12/2021	ASH Achievement Award
10/2019 – 03/2022	German Research Foundation (DFG) – Research Fellowship
07/2016 – 06/2018	Berlin Institute of Health – Junior Clinician Scientist Grant
09/2013 – 04/2014	German Academic Exchange Service (DAAD) – Exchange Scholarship
08/2013	Vienna Biocenter – VWR Summer School Prize
05/2010 – 11/2014	German Academic Scholarship Foundation – University Scholarship

Languages spoken

German	native	French	proficient
English	near-native	Romanian	proficient

Selected Publications

Dana-Farber Cancer Institute (since 2019)

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen NM, Pfaff KL, Cieri N, Oliveira G, Kim-Schulze S, Ranasinghe S, Leonard R, Robertson T, Morgan EA, Chen HX, Song MH, Thurin M, Li S, Rodig SJ, Cibulskis C, Gabriel S, Bachireddy P, Ritz J, Streicher H, Neuberg DS, Hodi FS, Davids MS, Gnjatic S, Livak KJ, Altreuter J, Michor F, Soiffer RJ, Garcia JS, Wu CJ
Blood. 2023 Apr 13;141(15):1817-1830. **IF 25.5**

Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models
Penter L*, ten Hacken E*, Southard J, Lareau CA, Ludwig LS, Li S, Neuberg DS, Livak KJ, Wu CJ
Cancer Research. 2023 Mar 2;83(5):667-672. **IF 12.7**

AML relapse after a TIGIT race
Penter L, Wu CJ
Blood. 2022 Sep 15;140(11):1189-1191. **IF 25.5**

Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics
Penter L, Gohil SH, Wu CJ
Frontiers in Immunology. 2022 12:788891. **IF 7.6**

Coevolving JAK2V617F^{+} relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
Penter L, Gohil SH, Huang T, Thrash EM, Schmidt D, Li S, Severgnini M, Neuberg DS, Hodi FS, Livak KJ, Zeiser R, Bachireddy P, Wu CJ
Blood Advances. 2021 5(22):4701-4709. **IF 6.7**

Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history
Penter L*, Gohil SH*, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ.
Cancer Discovery. 10.1158/2159-8290.CD-21-0276. 2021 **IF 39.4**

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, Chen H, Thurin M, Rodig SJ, Severgnini M, Cibulskis C, Gabriel S, Livak KJ, Cutler C, Antin JH, Nikiforow S, Koreth J, Ho VT, Armand P, Ritz J, Streicher H, Neuberg D, Hodi FS, Gnjatic S, Soiffer RJ, Liu XS, Davids MS, Bachireddy P, Wu CJ.
Blood. 2021 137 (23), 3212-3217. **IF 22.1**

Personal tumor antigens in blood malignancies: genomics-directed identification and targeting
Penter L, Wu CJ
JCI. 2020 130 (4), 1595-1607. **IF 14.8**

Charité – Universitätsmedizin Berlin (2015 – 2019)

Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer
Penter L, Dietze K, Ritter J, Lammoglia-Cobo MF, Garmshausen J, Aigner F, Bullinger L, Hackstein H, Wienzek-Lischka S, Blankenstein T, Hummel M, Dornmair K, Hansmann L.
OncoImmunology. 2019 8 (6), e1586409. **IF 5.9**

FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells
Penter L, Dietze K, Bullinger L, Westermann J, Rahn HP, Hansmann L.
Eur J Immunol. 2018 Jul;48(7):1248-1250. **IF 4.3**

A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma
Penter L, Maier B, Frede U, Hackner B, Carell T, Hagemeier C, Truss M.
Target Oncol. 2015 Dec;10(4):523-33. **IF 4.7**